Biopharmaceutical company Global Blood Therapeutics Inc. (GBT:NASDAQ), which is focused on the development of potentially life-changing medicines for sickle cell anemia and other diseases, yesterday announced "a new partnership with New York Jets running back Tevin Coleman and his wife, Akilah, whose 4-year-old daughter lives with sickle cell disease (SCD), with the goal of educating, inspiring, and raising awareness about SCD – especially among other parents and caregivers."
The firm noted that the campaign is kicking off ahead of World Sickle Cell Day which this year happens to fall on Father's Day, June 19, 2022. Global Blood Therapeutics advised that the Coleman family has offered to share their own personal story as part of the company's Sickle Cell Speaks education program. The company stated that the program was established to present the opportunity for afflicted individuals and family members to share their own authentic stories and experiences of living with sickle cell in order to increase awareness and dispel any misconceptions about the disease.
Tevin Coleman, who is an NFL running back with the New York Jets and sickle cell dad, remarked, "As a dad and husband, there's nothing more important than the health of my family. This World Sickle Cell Day and Father's Day, I am especially grateful for my daughter, Nazaneen, who lives and thrives with sickle cell disease."
Coleman added, "Too many children and adults with sickle cell go untreated, don't have regular checkups, and only get care when they suffer from symptoms. By sharing our family's story, we hope to inspire other families and warriors through their journeys to learn all they can and get the early and proactive care that's best for them."
The company stated that as part of its Sickle Cell Speaks campaign both Tevin and Akilah will be sharing what they refer to as their "playbook" for those families who are directly impacted by sickle cell disease. The couple is expected to actively participate in numerous appearances both in person and across social media with the goal of lending support and boosting engagement with the sickle cell community.
Global Blood Therapeutics' EVP and Head of R&D Kim Smith-Whitley, M.D., a pediatric hematologist with over 30 years of experience in caring for SCD patients, commented, "We are excited to partner with Tevin Coleman and his wonderful family to shine the light on their story as we join the sickle cell community in recognizing World Sickle Cell Day…The Colemans have taken important steps to build a foundation of healthy habits and support for their daughter that we hope will help other families create their own playbook for tackling sickle cell, along with the resources available on Sickle Cell Speaks."
Sickle Cell Disease (SCD) is a lifelong inherited blood disorder that is caused by a genetic mutation in the beta-chain of hemoglobin, which leads to the formation of abnormal hemoglobin known as sickle hemoglobin (HbS). Starting in early childhood, SCD patients typically experience unpredictable and recurrent episodes or crises of severe pain that is attributed to blocked blood flow to organs. The suffering undergone by these children often leads to psychosocial and physical disabilities.
The firm pointed out that Sickle cell disease (SCD) affects over 150,000 people combined in the U.S. and Europe and millions of others worldwide. Though it is most prevalent among those with ancestral roots in sub-Saharan Africa, it also is common in those with Hispanic, Middle Eastern, South Asian and Southern European origins. The company advised that of the roughly 100,000 people in the U.S. who have SCD, about 16,000 are children between the ages of 4 and 11 years old. The company stated that "early intervention and treatment of SCD have shown potential to modify the course of this disease, reduce symptoms and events, prevent long-term organ damage and extend life expectancy."
Global Blood Therapeutics is a biopharmaceutical company headquartered in South San Francisco, Calif. that is engaged in discovering, developing and providing life-changing medical treatments to patients in underserved communities. The firm is highly focused on the area of sickle cell disease (SCD). The company endeavors to transform the treatment of SCD, an area which the fundamental cause has been understood for decades, but that has lacked innovation in new therapeutics and access to care.
The company mentioned that it has developed the first FDA approved medicine called Oxbryta® (voxelotor) to address the underlying cause of SCD. GBT indicated that Oxbryta works by directly inhibiting sickle hemoglobin (HbS) polymerization, which it explained is the root cause of red blood cell sickling in individuals afflicted with SCD.
In addition, the firm's drug development pipeline includes several other compounds including a P-selectin inhibitor called inclacumab, which is presently being evaluated in a Phase 3 trial as a potential treatment to reduce the frequency of vaso-occlusive crises (VOCs) and reduce hospital re-admissions post-VOC. VOCs are the most commonly reported occurring complications associated with SCD that result in intense pain and potential irreversible organ damage.
Global Blood Therapeutics started the day with a market cap of around $1.5 billion with approximately 10.82 million shares outstanding. GBT shares opened slightly higher today at $24.16 (+$0.35, +1.47%) over yesterday's $23.81 closing price. The stock has traded today between $23.91 and $27.765 per share and is currently trading at $26.70 (+$2.89, +12.14%).
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Disclosure
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
